MedTrace Logo

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

NCT05345327 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 994

Last updated 2024-12-20

No results posted yet for this study

Summary

The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.

Conditions

Interventions

DRUG

Dapagliflozin

SGLT2 inhibitor

DRUG

Metformin

Metformin

Sponsors & Collaborators

  • The University of New South Wales

    collaborator OTHER

  • Monash University

    collaborator OTHER

  • University of Sydney

    collaborator OTHER

  • The George Institute

    lead OTHER

Principal Investigators

  • Bruce Neal · The George Institute for Global Health (Sydney, Australia)

  • Clare Arnott · The George Institute for Global Health (Sydney, Australia)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Australia
  • Sri Lanka

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05345327 on ClinicalTrials.gov